Novo Nordisk and Prothena announced that the U.S. Food and Drug Administration has granted Fast Track Designation to coramitug for transthyretin amyloidosis with cardiomyopathy (ATTR‑CM). The designation, which is intended to expedite the development and review of drugs that address serious conditions with unmet medical needs, was awarded on April 27, 2026.
Coramitug is a humanized monoclonal antibody that functions as an amyloid depleter, targeting and clearing misfolded, non‑native transthyretin (TTR) deposits while sparing the native TTR tetramer. This mechanism distinguishes it from existing ATTR therapies that stabilize the tetramer or silence TTR production. The Fast Track status is expected to facilitate more frequent FDA interactions and potentially a rolling review, accelerating the path to market approval.
The designation comes as coramitug is being evaluated in the Phase 3 CLEOPATTRA trial, which will enroll approximately 1,280 patients with ATTR‑CM and is projected to reach primary completion in 2029. Novo Nordisk acquired worldwide rights to Prothena’s ATTR amyloidosis program in July 2021 for up to $1.2 billion, including an upfront payment and milestone payments. Prothena is eligible for up to $1.2 billion in milestones, of which $150 million has already been earned, and the Fast Track status could enhance the likelihood of future milestone payments.
For Novo Nordisk, the Fast Track designation strengthens its portfolio in cardiovascular and rare disease space, adding a unique therapeutic approach that could capture a share of the growing ATTR market. For Prothena, the designation validates the potential of its amyloid‑depleting platform and may increase investor confidence in its pipeline, which also includes programs for Alzheimer’s and Parkinson’s disease.
The announcement underscores the strategic partnership between the two companies and highlights the importance of regulatory milestones in advancing novel therapies for rare diseases. The Fast Track status is a positive signal for both companies’ long‑term growth prospects in the ATTR therapeutic area.
The sentiment surrounding the announcement is positive, reflecting optimism about the accelerated development pathway and the potential financial upside for both Novo Nordisk and Prothena.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.